Style | Citing Format |
---|---|
MLA | Khojasteh Poor F, et al.. "Mini Review: The Fda-Approved Prescription Drugs That Target the Mapk Signaling Pathway in Women With Breast Cancer." Breast Disease, vol. 40, no. 2, 2021, pp. 51-62. |
APA | Khojasteh Poor F, Keivan M, Ramazii M, Ghaedrahmati F, Anbiyaiee A, Panahandeh S, Khoshnam SE, Farzaneh M (2021). Mini Review: The Fda-Approved Prescription Drugs That Target the Mapk Signaling Pathway in Women With Breast Cancer. Breast Disease, 40(2), 51-62. |
Chicago | Khojasteh Poor F, Keivan M, Ramazii M, Ghaedrahmati F, Anbiyaiee A, Panahandeh S, Khoshnam SE, Farzaneh M. "Mini Review: The Fda-Approved Prescription Drugs That Target the Mapk Signaling Pathway in Women With Breast Cancer." Breast Disease 40, no. 2 (2021): 51-62. |
Harvard | Khojasteh Poor F et al. (2021) 'Mini Review: The Fda-Approved Prescription Drugs That Target the Mapk Signaling Pathway in Women With Breast Cancer', Breast Disease, 40(2), pp. 51-62. |
Vancouver | Khojasteh Poor F, Keivan M, Ramazii M, Ghaedrahmati F, Anbiyaiee A, Panahandeh S, et al.. Mini Review: The Fda-Approved Prescription Drugs That Target the Mapk Signaling Pathway in Women With Breast Cancer. Breast Disease. 2021;40(2):51-62. |
BibTex | @article{ author = {Khojasteh Poor F and Keivan M and Ramazii M and Ghaedrahmati F and Anbiyaiee A and Panahandeh S and Khoshnam SE and Farzaneh M}, title = {Mini Review: The Fda-Approved Prescription Drugs That Target the Mapk Signaling Pathway in Women With Breast Cancer}, journal = {Breast Disease}, volume = {40}, number = {2}, pages = {51-62}, year = {2021} } |
RIS | TY - JOUR AU - Khojasteh Poor F AU - Keivan M AU - Ramazii M AU - Ghaedrahmati F AU - Anbiyaiee A AU - Panahandeh S AU - Khoshnam SE AU - Farzaneh M TI - Mini Review: The Fda-Approved Prescription Drugs That Target the Mapk Signaling Pathway in Women With Breast Cancer JO - Breast Disease VL - 40 IS - 2 SP - 51 EP - 62 PY - 2021 ER - |